Approval · Notice of Compliance 14879 · 2013
MOMETASONE: Notice of Compliance 14879
Issued November 5, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14879
- Date
- November 5, 2013
- Company
- Frosst A Division Of Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- To include in the 'clinical trials' section of the product monograph information related to previously reviewed clinical studies pertaining to both the seasonal allergic rhinitis (sar) and perennial allergic rhinitis (par) indications
- Therapeutic class
- Corticosteroid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MOMETASONE | Not yet assigned | — |
Medicinal ingredients
- MOMETASONE FUROATE 50 MCG per SPR